As predictive biomarker for enhanced pro-apoptotic and growth-inhibitory activity of ATO structural defects in the p53 gene have originally been described in models of B-cell lymphoma [10] and multiple myeloma [11], [12] which could also explain the low toxicity profile in normal cells expressing wildtype (wt) p53. This evidence concerns the gene TP53 and plasma cell myeloma.